SCHEMBL6078426

SCHEMBL6078426

COC(=O)C(O)=CC(=O)N(Cc1cccc2ccccc12)OC

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATM Q13315 2/20 0.42
CYP1A2 P05177 2/20 0.42
CYP2D6 P10635 2/20 0.42
CYP2C19 P33261 2/20 0.42
TDP1 Q9NUW8 3/20 0.41
KDM4E B2RXH2 1/20 0.41
ALDH1A1 P00352 1/20 0.41
HDAC1 Q13547 1/20 0.39
HDAC6 Q9UBN7 1/20 0.39
L3MBTL1 Q9Y468 3/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
NR1I2 O75469 1/20 0.39
DRD2 P14416 1/20 0.39
ADRA2C P18825 1/20 0.39
CNR1 P21554 1/20 0.39
SLC6A2 P23975 1/20 0.39
HTR2A P28223 1/20 0.39
SLC6A4 P31645 1/20 0.39
ADRA1A P35348 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6077209 0.86 CYP1A2 (0.47) ATMCYP1A2CYP2D6CYP2C19TDP1
SCHEMBL6077454 0.84 KMT2A (0.38) TDP1KDM4EALDH1A1MEN1KMT2A
SCHEMBL6077452 0.84 KMT2A (0.38) TDP1KDM4EALDH1A1MEN1KMT2A
SCHEMBL6077550 0.82 ALDH1A1 (0.43) ATMKDM4EALDH1A1L3MBTL1MEN1
SCHEMBL6077547 0.82 ALDH1A1 (0.43) ATMKDM4EALDH1A1L3MBTL1MEN1
SCHEMBL6076994 0.79 TSPO (0.40) TDP1KDM4EALDH1A1MEN1KMT2A
SCHEMBL6077002 0.79 TSPO (0.40) TDP1KDM4EALDH1A1MEN1KMT2A
SCHEMBL6077726 0.74 CYP1A2 (0.38) ATMCYP1A2CYP2D6CYP2C19TDP1
SCHEMBL6077728 0.74 CYP1A2 (0.38) ATMCYP1A2CYP2D6CYP2C19TDP1
SCHEMBL6078402 0.73 RIPK1 (0.41) KDM4EALDH1A1SLC6A2HTR2ASLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7109186-B2 4-hydroxy-5-oxo-1-(2-[4-methylpiperazin-1-yl]ethyl)-2,5-dihydro-1H-pyrrole-3-carboxylic acid (3,4-dichlorobenzyl)-methyl-amide for human immunodeficiency virus (HIV) treatment BRISTOL-MYERS SQUIBB COMPANY (US) 2006-09-19 US disclosed
US-20040110804-A1 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2004-06-10 US disclosed
WO-2004004657-A2 HIV INTEGRASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2004-01-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110804-A1 HIV integrase inhibitors CDKN1A, SAMHD1, CTCF ATM 1262/4885CYP1A2 483/4885CYP2D6 1226/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.